A Randomized Open-label Study to Evaluate the Sustained Virologic Response of Danoprevir/Ritonavir and Copegus in Combination With RO5024048 and/or Pegasys in Chronic Hepatitis C Genotype 1 Patients Who Failed Previous Standard Therapy

Trial Profile

A Randomized Open-label Study to Evaluate the Sustained Virologic Response of Danoprevir/Ritonavir and Copegus in Combination With RO5024048 and/or Pegasys in Chronic Hepatitis C Genotype 1 Patients Who Failed Previous Standard Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2016

At a glance

  • Drugs Danoprevir (Primary) ; Mericitabine (Primary) ; Peginterferon alfa-2a; Ribavirin; Ritonavir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms MATTERHORN
  • Sponsors Roche
  • Most Recent Events

    • 25 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jan 2013 Planned end date changed from 1 Jun 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 13 Oct 2011 Status changed from recruiting to active, no longer recruiting; enrollment was completed in the third quarter of 2011, according to a Roche presentation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top